Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Meredith Ann McKean"'
Autor:
Nehal Lakhani, Kristi Manjarrez, Meredith Ann McKean, Amita Patnaik, Stanford L. Peng, Z. Goldberg, Michael Chisamore, Hany Zayed
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDespite successes with checkpoint inhibition (CPI) in a wide range of tumors, most patients demonstrate primary or acquired resistance, thus driving the need for better IO therapy. Research has suggested that CPI therapy exerts much of its
Autor:
Rodabe N. Amaria, Meredith Ann McKean
Publikováno v:
American Journal of Clinical Dermatology. 19:639-646
Locally advanced and metastatic melanoma have historically had poor survival outcomes. Long-term follow-up of both targeted therapies and immune checkpoint inhibitors has confirmed the survival benefit of these agents in stage IV melanoma, and recent
Autor:
Rodabe N. Amaria, Meredith Ann McKean
Publikováno v:
Clinical Skin Cancer. 2:32-38
Treatment strategies in metastatic melanoma have attempted to use the immune system to target cancer since the 1980s. Adoptive cell transfer using autologous tumor-infiltrating lymphocytes (TILs) extracted from a patient tumor and cultured in vitro w
Autor:
Laura Sierra, Tom Zimmerman, Shiraj Sen, Melinda S. Merchant, Jessica Ainscough, Jay Yang, Meredith Ann McKean, Anthony Hamlett, Sant P. Chawla
Publikováno v:
Journal of Clinical Oncology. 38:TPS11573-TPS11573
TPS11573 Background: Epithelioid sarcoma (ES) is characterized by loss of inhibitor of integrase 1 (INI1), allowing enhancer of zeste homologue 2 (EZH2) to repress cell differentiation and promote tumorigenesis. Tazemetostat (TAZ) is an EZH2 inhibito
Autor:
Alan E. Siroy, Junsheng Ma, Alexander J. Lazar, Phuong Vo, Scott E. Woodman, Fernando Carapeto, Mariana Petaccia de Macedo, Keyur P. Patel, Katherine G. Roth, Agda Karina Eterovic, Junna Oba, Roland L. Bassett, Elizabeth A. Grimm, Meredith Ann McKean, David S. Hong, Lauren E. Haydu, Wei Lien Wang
Publikováno v:
The Journal of investigative dermatology. 139(3)
Autor:
Rodabe N. Amaria, Meredith Ann McKean
Publikováno v:
Cancer treatment reviews. 70
Stage III melanoma encompasses a range of disease burdens, including microscopic foci of metastatic melanoma in a sentinel lymph node; bulky, clinically detected lymphadenopathy; and in-transit dermal metastases. After initial surgical management, pa
Autor:
Wei-Lien Wang, Charuta Kale, Cara Haymaker, Meredith Ann McKean, David S. Hong, Lauren E. Haydu, Mark J. Routbort, Alexander J. Lazar, Elizabeth A. Grimm, Chantale Bernatchez, Agda Karina Eterovic, Fernando Carapeto, Xiaoxing Yu, Scott E. Woodman, Sun-Hee Kim, Mariana Petaccia de Macedo, Junna Oba, Shiraj Sen, John S. Van Arnam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::901d325bb5d762c8cb1785182b7a2dcd
https://europepmc.org/articles/PMC6080631/
https://europepmc.org/articles/PMC6080631/
Autor:
Jean-Jacques Grob, Daniel Y. Wang, Jeffrey A. Sosman, Christine N. Spencer, Michael A. Davies, John J. Park, Shenying Fang, Stephen R. Lane, Yibing Yan, Kenneth R. Hess, Dirk Schadendorf, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul B. Chapman, Jennifer A. Wargo, Samuel M. Rubinstein, John M. Kirkwood, Jennifer L. McQuade, Edward McKenna, Jeffrey J. Legos, Dana Walker, Tomas Haas, Theodore S. Nowicki, Kathryn E. Beckermann, Meredith Ann McKean, Lauren E. Haydu, Alexander M. Menzies, Antoni Ribas, Carrie R. Daniel, Patrick Hwu, Mathilde Kaper, Nageshwar Budha, Matteo S. Carlino, Maneka Puligandla, Jessie Hao-Ru Hsu, Dung Yang Lee, Carmen Mak, Sandra J. Lee, Douglas B. Johnson, Alexandre Avila, Keith T. Flaherty, Matthew Wongchenko, Rajat Rai, Luna Musib, Isabelle Rooney, Georgina V. Long
Publikováno v:
The Lancet. Oncology, vol 19, iss 3
McQuade, JL; Daniel, CR; Hess, KR; Mak, C; Wang, DY; Rai, RR; et al.(2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. LANCET ONCOLOGY, 19(3), 310-322. doi: 10.1016/S1470-2045(18)30078-0. UCLA: Retrieved from: http://www.escholarship.org/uc/item/39f4d1hw
McQuade, JL; Daniel, CR; Hess, KR; Mak, C; Wang, DY; Rai, RR; et al.(2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. LANCET ONCOLOGY, 19(3), 310-322. doi: 10.1016/S1470-2045(18)30078-0. UCLA: Retrieved from: http://www.escholarship.org/uc/item/39f4d1hw
Summary Background Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between bod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2649e6bfacc9346cfe65a6933623d4d
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85041944438
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85041944438
Autor:
Meredith Ann McKean, Eileen Shiuan, Michael A. Postow, John P. Greer, Kathryn E. Beckermann, Ciara Marie Kelly, Michael A. Davies, Douglas B. Johnson, Zeynep Eroglu, Igor Puzanov, Alpaslan Özgün, Jennifer L. McQuade, Suthee Rapisuwon, Mary Ann Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs)
Autor:
Victoria Atkinson, Michael Millward, Robert Mason, Meredith Ann McKean, Rodabe N. Amaria, Serigne Lo, Daniel Ying Wang, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Cathy Yi Xia, Douglas B. Johnson, Georgina V. Long, Jennifer L. McQuade, Jessica Smith
Publikováno v:
Journal of Clinical Oncology. 36:9532-9532
9532Background: There are limited data regarding the best sequence of targeted and immunotherapy in patients (pts) with BRAF-mutant melanoma. Some studies suggest lower activity of immunotherapy af...